4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide has been researched along with Insulin Resistance in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, M; Funaki, M; Hou, H; Hu, X; Li, Q; Liu, Y; Nakaya, Y; Shen, Q; Wu, Q; Xiao, J; Yin, W; Zhang, C | 1 |
| Wang, YT; Wang, ZB; Wei, HS; Yi, GH; Yin, WD; Yu, J; Zeng, HC; Zhang, YL | 1 |
| Fan, J; Koike, T; Kusunoki, M; Lian, X; Liao, D; Tang, C; Tsutsumi, K; Wang, Z; Xi, S; Yang, Y; Yin, W | 1 |
| Cai, M; Hou, H; Li, J; Li, Q; Liao, D; Liu, Y; Tsutsumi, K; Wang, Z; Xiao, J; Yin, W; Zhang, C | 1 |
| Hara, T; Kusunoki, M; Miyata, T; Nakamura, T; Nakaya, Y; Ogawa, H; Sakakibara, F; Sakamoto, S; Storlien, LH; Tsutsumi, K | 1 |
| Fukuzawa, Y; Hara, T; Kakumu, S; Kusunoki, M; Miyata, T; Nakamura, T; Nakaya, Y; Ogawa, H; Sakakibara, F; Suga, T; Tsutsumi, K | 1 |
6 other study(ies) available for 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and Insulin Resistance
| Article | Year |
|---|---|
NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1.
Topics: Animal Feed; Animals; Benzamides; Cell Line, Tumor; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Drug Administration Schedule; Humans; Hyperglycemia; Hyperinsulinism; Hypolipidemic Agents; Insulin Resistance; Insulin-Like Growth Factor I; Liver; Male; Organophosphorus Compounds; STAT5 Transcription Factor; Swine; Swine, Miniature; Up-Regulation | 2010 |
NO-1886 ameliorates glycogen metabolism in insulin-resistant HepG2 cells by GSK-3β signalling.
Topics: Benzamides; Cells, Cultured; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Glycogenolysis; Hep G2 Cells; Humans; Insulin Resistance; Lipoprotein Lipase Activators; Organophosphorus Compounds; Palmitates; Real-Time Polymerase Chain Reaction; Signal Transduction; Statistics as Topic | 2012 |
NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in diet-induced diabetic swine.
Topics: Animals; Benzamides; Diabetes Mellitus; Dietary Carbohydrates; Dietary Fats; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Lipid Metabolism; Liver; Male; Models, Animal; Muscle, Skeletal; Myocardium; Organophosphorus Compounds; Swine, Miniature | 2004 |
Effects of NO-1886 on inflammation-associated cytokines in high-fat/high-sucrose/high-cholesterol diet-fed miniature pigs.
Topics: Animals; Atherosclerosis; Benzamides; Cholesterol, Dietary; Cytokines; Diabetes Mellitus; Dietary Carbohydrates; Dietary Fats; Glucose Tolerance Test; Hypolipidemic Agents; Inflammation; Insulin; Insulin Resistance; Lipids; Male; Organophosphorus Compounds; Sucrose; Swine; Swine, Miniature; Tunica Intima | 2006 |
The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet.
Topics: Adipose Tissue; Animals; Benzamides; Blood Glucose; Dietary Fats; Enzyme Activation; Fatty Acids, Nonesterified; Glucose Clamp Technique; Hyperinsulinism; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Insulin Resistance; Lipoprotein Lipase; Male; Myocardium; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Triglycerides | 2000 |
Correlation between lipid and glycogen contents in liver and insulin resistance in high-fat-fed rats treated with the lipoprotein lipase activator NO-1886.
Topics: Animals; Benzamides; Blood Glucose; Body Weight; Cholesterol; Dietary Fats; Enzyme Activation; Glucose Clamp Technique; Glycogen; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Lipids; Lipoprotein Lipase; Liver; Male; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Triglycerides | 2002 |